Covid19 Clinical Trial - A Study of FOY-305 in Patients With SARS-Cov-2

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT04483960` - Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial	Phase 3
	Completed	`NCT04416334` - PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 60 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS	Phase 3

See also

Status

Clinical Trial

Phase

Active, not recruiting

NCT04483960 - Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial

Phase 3

Completed

NCT04416334 - PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 60 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS

Phase 3

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT04657497
Study type	Interventional
Source	Ono Pharmaceutical Co. Ltd
Contact
Status	Completed
Phase	Phase 3
Start date	November 9, 2020
Completion date	April 9, 2021

A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms